Malik Y. Kahook - 05 Feb 2026 Form 4 Insider Report for SpyGlass Pharma, Inc. (SGP)

Reporting relationship: President, Chief Medical Officer, Executive Chair, Director
Issuer ticker: SGP
Reported as of: 05 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Feb 2026, 16:41:38 UTC
Source filing: View source filing
Reporting owner signature: /s/ Brian Aukshunas, as Attorney-in-Fact

Key filing fact

Malik Y. Kahook filed Form 4 for SpyGlass Pharma, Inc. (SGP) on 09 Feb 2026.

Key facts

This page summarizes Malik Y. Kahook's Form 4 filing for SpyGlass Pharma, Inc. (SGP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Feb 2026, 16:41.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002106409 Primary reporting owner

Kahook Malik Y.

Relationship: President, Chief Medical Officer, Executive Chair, Director
Address: C/O SPYGLASS PHARMA, INC., 27061 ALISO CREEK RD., SUITE 100, ALISO VIEJO
Signature: /s/ Brian Aukshunas, as Attorney-in-Fact
Signature date: 09 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGP transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +105,000
Change %
Price: $0.000000
Shares after: 105,000
Date: 05 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 105,000
Exercise price: $16.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.

SEC remarks

President, Chief Medical Officer, Executive Chair